A therapeutic approach to minimize residual disease and relapse in cancer

Case ID:
2413
Web Published:
1/18/2019
Description:

Technology Summary

OHSU researchers have identified a novel treatment method which, when used in combination with first-line cancer therapies, has the potential to minimize residual disease, the primary cause of relapse in all cancers.  The method leverages existing drugs that inhibit a metabolic target molecule not previously understood to be involved in autophagy, a biological mechanism that supports tumor cell survival.  Inhibition of this target, combined with standard therapy, can be used to treat cancers more effectively.

 

Intellectual Property

Patent Application Filed

 

Licensing Opportunity

This technology is available for exclusive licensing and/or collaborative co-development. 

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Anne Carlson
Technology Development Manager
Oregon Health & Science University
503-494-7809
carlsann@ohsu.edu
Inventors:
George Thomas
Hui-wen Lue
Jennifer Podolak
Kevin Kolahi
Keywords:
Therapeutics - Cancer
© 2020. All Rights Reserved. Powered by Inteum